232 related articles for article (PubMed ID: 35732329)
1. Molecular Analysis of Luminal Androgen Receptor Reveals Activated Pathways and Potential Therapeutic Targets in Breast Cancer.
Stella S; Vitale SR; Massimino M; Motta G; Longhitano C; Lanzafame K; Martorana F; Fazzari C; Vecchio GM; Tirrò E; Inzerilli N; Carciotto R; Manzella L; Caruso M; Vigneri P
Cancer Genomics Proteomics; 2022; 19(4):464-476. PubMed ID: 35732329
[TBL] [Abstract][Full Text] [Related]
2. Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts.
Coussy F; Lavigne M; de Koning L; Botty RE; Nemati F; Naguez A; Bataillon G; Ouine B; Dahmani A; Montaudon E; Painsec P; Chateau-Joubert S; Laetitia F; Larcher T; Vacher S; Chemlali W; Briaux A; Melaabi S; Salomon AV; Guinebretiere JM; Bieche I; Marangoni E
Theranostics; 2020; 10(4):1531-1543. PubMed ID: 32042320
[TBL] [Abstract][Full Text] [Related]
3. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
[TBL] [Abstract][Full Text] [Related]
4. In vitro effect of PIK3CA/mTOR inhibition in triple-negative breast cancer subtype cell lines.
Kumar S; Bhattacharyya S; Das A; Singh G; Bal A
Breast Dis; 2022; 41(1):241-247. PubMed ID: 35431224
[TBL] [Abstract][Full Text] [Related]
5. Molecular characterization of metaplastic breast carcinoma via next-generation sequencing.
Zhai J; Giannini G; Ewalt MD; Zhang EY; Invernizzi M; Niland J; Lai LL
Hum Pathol; 2019 Apr; 86():85-92. PubMed ID: 30537493
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase pathway genomic alterations in 60,991 diverse solid tumors informs targeted therapy opportunities.
Millis SZ; Jardim DL; Albacker L; Ross JS; Miller VA; Ali SM; Kurzrock R
Cancer; 2019 Apr; 125(7):1185-1199. PubMed ID: 30582752
[TBL] [Abstract][Full Text] [Related]
8. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
9. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
[TBL] [Abstract][Full Text] [Related]
10. The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Ng CKY; Piscuoglio S; Geyer FC; Burke KA; Pareja F; Eberle CA; Lim RS; Natrajan R; Riaz N; Mariani O; Norton L; Vincent-Salomon A; Wen YH; Weigelt B; Reis-Filho JS
Clin Cancer Res; 2017 Jul; 23(14):3859-3870. PubMed ID: 28153863
[No Abstract] [Full Text] [Related]
11. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
[TBL] [Abstract][Full Text] [Related]
12.
Amato O; Buisseret L; Gebhart G; Plouznikoff N; Larsimont D; Awada A; Piccart M; Aftimos P
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 36863843
[TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
14. Genomic characterization reveals distinct mutational landscapes and therapeutic implications between different molecular subtypes of triple-negative breast cancer.
Li RQ; Yan L; Zhang L; Ma HX; Wang HW; Bu P; Xi YF; Lian J
Sci Rep; 2024 May; 14(1):12386. PubMed ID: 38811720
[TBL] [Abstract][Full Text] [Related]
15. Spectrum of PIK3CA/AKT mutations across molecular subtypes of triple-negative breast cancer.
Kumar S; Bal A; Das A; Loriya I; Khare S; Bhattacharya S; Singh G
Breast Cancer Res Treat; 2021 Jun; 187(3):625-633. PubMed ID: 33954864
[TBL] [Abstract][Full Text] [Related]
16. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer.
Browne IM; André F; Chandarlapaty S; Carey LA; Turner NC
Lancet Oncol; 2024 Apr; 25(4):e139-e151. PubMed ID: 38547898
[TBL] [Abstract][Full Text] [Related]
17. Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses.
Fumagalli C; Ranghiero A; Gandini S; Corso F; Taormina S; De Camilli E; Rappa A; Vacirca D; Viale G; Guerini-Rocco E; Barberis M
Breast Cancer Res; 2020 Oct; 22(1):107. PubMed ID: 33059724
[TBL] [Abstract][Full Text] [Related]
18. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
[TBL] [Abstract][Full Text] [Related]
19. Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer.
Robles AJ; Cai S; Cichewicz RH; Mooberry SL
Breast Cancer Res Treat; 2016 Jun; 157(3):475-88. PubMed ID: 27255535
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
